• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

    456.95 +6.27 (+1.39%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 9, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,051,961
    Open 451.00
    Bid (Size) 429.66 (1)
    Ask (Size) 460.00 (5)
    Prev. Close 450.68
    Today's Range 448.83 - 459.57
    52wk Range 205.87 - 484.21
    Shares Outstanding 118,847,693
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
    Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
    Via MarketMinute
    ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) Shows Strong Technical Setup for Potential Breakout
    Alnylam Pharmaceuticals (ALNY) presents a strong technical breakout setup with a high rating for both trend momentum and consolidation quality. 
    Via Chartmill

    Performance

    YTD
    +95.6%
    +95.6%
    1 Month
    -5.2%
    -5.2%
    3 Month
    +41.6%
    +41.6%
    6 Month
    +101.9%
    +101.9%
    1 Year
    +68.7%
    +68.7%

    More News

    Read More
    27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know
    Via Benzinga
    Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape
    Via MarketMinute
    Topics Artificial Intelligence Economy Government
    New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Pharma Tariffs Back In Spotlight On New Trump Threat
    Via Investor's Business Daily
    Topics ETFs Government World Trade
    Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
    Via Benzinga
    Beyond The Numbers: 28 Analysts Discuss Alnylam Pharmaceuticals Stock
    Via Benzinga
    Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Here's How Much $1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
    Via Benzinga
    $1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Where Alnylam Pharmaceuticals Stands With Analysts
    Via Benzinga
    New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Alnylam to Webcast Presentations at Upcoming September Investor Conferences
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    A Closer Look at Alnylam Pharmaceuticals's Options Market Dynamics
    Via Benzinga
    How Is The Market Feeling About Alnylam Pharmaceuticals?
    Via Benzinga
    Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
    Via Benzinga
    Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Where Alnylam Pharmaceuticals Stands With Analysts
    Via Benzinga
    Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today
    Via Benzinga

    Frequently Asked Questions

    Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
    Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
    What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
    The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 456.95
    When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 10/09/25 04:00 PM ET
    What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 54.31B
    How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
    Alnylam Pharmaceuticals, Inc. - Common Stock has 54B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.